0001437749-17-015577.txt : 20170905 0001437749-17-015577.hdr.sgml : 20170904 20170905163002 ACCESSION NUMBER: 0001437749-17-015577 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20170901 FILED AS OF DATE: 20170905 DATE AS OF CHANGE: 20170905 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: SANDBERG RICHARD A CENTRAL INDEX KEY: 0001245055 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36200 FILM NUMBER: 171069057 MAIL ADDRESS: STREET 1: 330 NEVEDA STREET CITY: NEWTON STATE: MA ZIP: 02460-1458 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Oxford Immunotec Global PLC CENTRAL INDEX KEY: 0001586049 STANDARD INDUSTRIAL CLASSIFICATION: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835] IRS NUMBER: 000000000 STATE OF INCORPORATION: X0 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 94C INNOVATION DRIVE STREET 2: MILTON PARK CITY: ABINGDON STATE: X0 ZIP: OX14 4RZ BUSINESS PHONE: 44 01235 442780 MAIL ADDRESS: STREET 1: 94C INNOVATION DRIVE STREET 2: MILTON PARK CITY: ABINGDON STATE: X0 ZIP: OX14 4RZ 4 1 rdgdoc.xml FORM 4 X0306 4 2017-09-01 0001586049 Oxford Immunotec Global PLC OXFD 0001245055 SANDBERG RICHARD A C/O OXFORD IMMUNOTEC GLOBAL PLC 94C INNOVATION DRIVE ABINGDON, OXFORDSHIRE X0 OX14 4RZ UNITED KINGDOM 1 Ordinary Shares 2017-09-01 4 M 0 3000 0.81 A 18000 D Ordinary Shares 2017-09-01 4 S 0 3000 15.8199 D 15000 D Stock Option (Right to Buy) 0.81 2017-09-01 4 M 0 3000 0 D 2022-12-31 Ordinary Shares 3000 2778 D The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 1, 2017. The price reported for the sales on September 1, 2017 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.7601 to $15.9000 per share, inclusive. The reporting person undertakes to provide Oxford Immunotec Global PLC, or any of its security holders, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (3) to this Form 4. Exercise from an option granted November 7, 2012, which became fully vested on December 31, 2016. /s/ Elizabeth M. Keiley, as Attorney-in-Fact for Richard A. Sandberg 2017-09-05